甲状腺乳头状癌中复发性LMO7-BRAF融合基因的鉴定
研究对12例甲状腺乳头状癌(PTC)肿瘤及配对非受累甲状腺组织进行RNA测序分析基因融合,并在148例PTC肿瘤样本中筛查LMO7-BRAF融合与BRAFV600E突变。发现LMO7-BRAF融合为复发性体细胞改变,频率2.0%(3/148),而BRAFV600E突变频率为63.5%(94/148)。强制表达LMO7-BRAF融合蛋白可刺激内源性ERK1/2磷酸化并促进锚定非依赖性细胞生长,程度与BRAFV600E相似。
要点
- 在PTC肿瘤中鉴定出新型LMO7-BRAF融合基因。
- LMO7-BRAF融合在PTC中为复发性体细胞改变,频率2.0%(3/148)。
- LMO7-BRAF融合蛋白可刺激ERK1/2磷酸化并促进锚定非依赖性生长,程度与BRAFV600E相似。
核心结论
- 在PTC肿瘤中鉴定出新型融合基因LMO7-BRAF,结果提示该融合表现为致癌性改变,扩展了甲状腺癌中涉及激酶的融合基因谱。
研究设计与样本
- 对12例PTC肿瘤及配对非受累甲状腺组织的RNA测序数据进行分析基因融合,候选融合经逆转录聚合酶链反应、Sanger测序和荧光原位杂交进一步过滤和验证。
- 在148例PTC肿瘤样本的Ohio队列中筛查LMO7-BRAF融合和BRAFV600E突变,并进行功能实验评估LMO7-BRAF融合。
主要发现
- 在两个肿瘤样本中各发现一个编码融合(CCDC6-RET和LMO7-BRAF)。
- 新型LMO7-BRAF融合经逆转录聚合酶链反应和荧光原位杂交验证。
- LMO7-BRAF融合为复发性体细胞改变,在PTC肿瘤中频率为2.0%(3/148);BRAFV600E点突变在肿瘤中频率为63.5%(94/148)。
- 强制表达LMO7-BRAF融合蛋白可刺激内源性ERK1/2磷酸化并促进锚定非依赖性细胞生长,程度与BRAFV600E相似。
关键数值与推荐
- LMO7-BRAF融合在PTC肿瘤中频率为2.0%(3/148)。
- BRAFV600E点突变在PTC肿瘤中频率为63.5%(94/148)。
临床怎么用
- 原文未报告临床实践建议。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The BRAFV600E mutation is the most common driver in papillary thyroid carcinoma (PTC) tumors. In recent years, gene fusions have also been recognized as important drivers of cancer in PTC. Previous studies have suggested that thyroid tumors with fusion genes frequently display an aggressive course. These observations prompted further exploration of gene fusions in PTC tumors. The aim was to search for previously unrecognized gene fusions using thyroid tissue samples from PTC patients. METHODS: Gene fusions were analyzed in RNA sequencing data obtained from 12 PTC tumors and paired unaffected thyroid tissue samples. Candidate fusions were further filtered and validated using reverse transcriptase polymerase chain reaction, Sanger sequencing, and fluorescence in situ hybridization. An Ohio cohort of 148 PTC tumor samples was screened for a LMO7-BRAF fusion and the BRAFV600E mutation. Functional assays were performed to assess the LMO7-BRAF fusion. RESULTS: Two coding fusions (CCDC6-RET and LMO7-BRAF) were found in one tumor sample each. The novel LMO7-BRAF fusion was validated by reverse transcriptase polymerase chain reaction and fluorescence in situ hybridization. The LMO7-BRAF fusion was a recurrent somatic alteration with a frequency of 2.0% (3/148) in PTC tumors, while the BRAFV600E point mutation was found in 63.5% (94/148) of tumors. Enforced expression of LMO7-BRAF fusion protein stimulated endogenous ERK1/2 phosphorylation and promoted anchorage independent cell growth to an extent similar to BRAFV600E. CONCLUSIONS: A novel fusion gene, LMO7-BRAF, was identified in PTC tumors. The results indicate that the LMO7-BRAF fusion behaves as an oncogenic alteration. This observation expands the spectrum of fusion genes involving kinases in thyroid cancer.
引用
- He H, Li W, Yan P, et al. Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma. Thyroid. 2018. PMID: 29768105. doi:10.1089/thy.2017.0258
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。